Caroline Dartigeas
Overview
Explore the profile of Caroline Dartigeas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
1176
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nguyen-Khac F, Baron M, Guieze R, Feugier P, Fayault A, Raynaud S, et al.
Br J Haematol
. 2024 Apr;
205(2):495-502.
PMID: 38654616
The potential prognostic influence of genetic aberrations on chronic lymphocytic leukaemia (CLL) can vary based on various factors, such as the immunoglobulin heavy variable (IGHV) status. We conducted an integrative...
2.
Dartigeas C, Quinquenel A, Ysebaert L, Dilhuydy M, Anglaret B, Slama B, et al.
Ann Hematol
. 2024 Mar;
PMID: 38443660
We conducted an observational study (FIRE) to understand the effectiveness and safety outcomes of ibrutinib in patients with chronic lymphocytic leukemia (CLL) in France, after a maximum follow-up of five...
3.
Carras S, Torroja A, Emadali A, Montaut E, Daguindau N, Tempescul A, et al.
Haematologica
. 2023 Nov;
109(6):1857-1865.
PMID: 38031755
Between 2011 and 2012, a phase II trial evaluated the use of the RiBVD (rituximab, bendamustine, velcade and dexamethasone) combination as first-line treatment for mantle cell lymphoma (MCL) patients over...
4.
Zinzani P, Trneny M, Ribrag V, Zilioli V, Walewski J, Haaber Christensen J, et al.
EClinicalMedicine
. 2023 Aug;
62:102131.
PMID: 37599908
Background: Parsaclisib is a potent and highly selective PI3Kδ inhibitor that has shown clinical benefit in patients with relapsed/refractory (R/R) B-cell malignancies. In this phase 2 study (CITADEL-205; NCT03235544, EudraCT...
5.
Michallet A, Letestu R, Le Garff-Tavernier M, Campos L, Ticchioni M, Dilhuydy M, et al.
Blood Adv
. 2023 Apr;
7(15):3936-3945.
PMID: 37026799
In previously untreated, medically fit patients with chronic lymphocytic leukemia (CLL), research is focused on developing fixed-duration strategies to improve long-term outcomes while sparing patients from serious toxicities. The ICLL-07...
6.
Broseus J, Hergalant S, Vogt J, Tausch E, Kreuz M, Mottok A, et al.
Nat Commun
. 2023 Jan;
14(1):309.
PMID: 36658118
Richter syndrome (RS) is the transformation of chronic lymphocytic leukemia (CLL) into aggressive lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL). We characterize 58 primary human RS samples by genome-wide...
7.
Bouclet F, Krzisch D, Leblond V, Tomowiak C, Laribi K, Ysebaert L, et al.
Bull Cancer
. 2022 Oct;
110(1):88-100.
PMID: 36229266
Waldenström's disease is a B-cell neoplasm characterized by the accumulation of lymphoplasmacytic cells (LPCs) in the bone marrow, and more rarely in the lymph nodes and the spleen, which produce...
8.
Dartigeas C, Slama B, Doyle M, Tapprich C, Albrecht C, Dupuis S, et al.
Clin Hematol Int
. 2022 Sep;
4(3):65-74.
PMID: 36103041
The FIRE study investigated the real-world effectiveness and safety of ibrutinib in prospectively observed patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL) in France....
9.
Laribi K, Baugier de Materre A, Ghez D, Dartigeas C, Tomowiak C, Mahe B, et al.
Hemasphere
. 2022 Jun;
6(6):e716.
PMID: 35747848
No abstract available.
10.
Bouard L, Tessoulin B, Thieblemont C, Bouabdallah K, Gastinne T, Oberic L, et al.
Haematologica
. 2022 Feb;
107(9):2163-2172.
PMID: 35172560
Rituximab maintenance (RM) after autologous stem cell transplantation (ASCT) is standard-of-care for young patients with mantle cell lymphoma (MCL). RM may enhance post-transplantation immune depression and risk of infections. We...